Top Markets
#1 Islamic Coin Islamic Coin +151.48%
#2 DOVU DOVU +48.81%
#3 Black Phoenix Black Phoenix +34.68%
#4 Velvet Velvet +30.25%
#5 Cross Cross +21.75%
#6 Akedo Akedo +18.18%
#7 DoubleZero DoubleZero +14.26%
#8 Cap Cap +11.23%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.05%
#10 HOME HOME +11.00%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Classement en actions #39464
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Prix de l'action
$0.11725176
Dernière synchronisation: 2025-07-14
Capitalisation boursière
$481.50K
Changement (1 jour)
-0.20%
Changement (1 an)
0.00%
Pays
FR
Échange PHAXIAM Therapeutics S.A. (PHXM)

Catégorie

Healthcare
Revenus pour PHAXIAM Therapeutics S.A. (PHXM)
Revenus en Jun 2024 TTM : $2.30M
Selon les derniers rapports financiers de PHAXIAM Therapeutics S.A., le chiffre d'affaires actuel de l'entreprise (TTM) est de $2.30M. En 2022, l'entreprise a réalisé un chiffre d'affaires de $7.13M une augmentation par rapport à le chiffre d'affaires de l'année 2021, qui était de $4.75M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour PHAXIAM Therapeutics S.A. de 2016 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) $2.30M 56.82%
2023 $1.47M -79.44%
2022 $7.13M 50.00%
2021 $4.75M 4.97%
2020 $4.53M -23.61%
2019 $5.93M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 549,098.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 261,845.69%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 439,752.28%
BE